Your session is about to expire
← Back to Search
KRT-232 for Small Cell Lung Cancer
This trial will assess the safety and efficacy of KRT-232 in treating patients with small cell lung cancer that has progressed after prior treatment.
- Small Cell Lung Cancer
Inclusion CriteriaYou will be eligible if you check “Yes” for the criteria below
Study ObjectivesOutcome measures can provide a clearer picture of what you can expect from a treatment.
Awards & Highlights
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Are we still looking for test subjects for this experiment?
"This trial is actively recruiting patients, based on the information available on clinicaltrials.gov. The trial was first posted on December 6th, 2021, and was most recently updated on June 15th, 2022."
Does KRT-232 have a history of being studied?
"The development of KRT-232 began in 2017 at Huntsman Cancer Institute/University of Utah. Since then, 3 studies have completed and 13 more are underway; several of these latter trials taking place in Fort Myers, Ohiof Utah. Since then, 3 studies have completed and 13 more are underway; several of these latter trials taking place in Fort Myers, Ohio."
How many people are included in this clinical trial?
"In order to carry out the study, 38 patients that meet the eligibility requirements must be recruited. Kartos Therapeutics, Inc. will oversee the trial from various locations, such as Florida Cancer Specialists - 3840 Broadway in Fort Myers and University Hospitals Cleveland Medical Center situated in Cleveland, Tennessees Florida Cancer Specialists - 3840 Broadway in Fort Myers and University Hospitals Cleveland Medical Center situated in Cleveland, Tennessee."
Is this clinical trial taking place in multiple hospitals across the state?
"Currently, 9 different facilities are running this clinical trial. Some notable locations include Florida Cancer Specialists - 3840 Broadway in Fort Myers, University Hospitals Cleveland Medical Center in Cleveland, and Florida Cancer Specialists in West Palm Beach."
What sorts of side effects does KRT-232 have on patients?
"Given that this is a Phase 2 trial and there is only data supporting safety but no efficacy, our team has given KRT-232 a score of 2."
Share this study with friends